OBJECTIVE: The objective of this study was to describe the efficacy of sodium thiosulphate (STS) in tumoral calcinosis (TC). METHODS: The methodology involved the reporting of four retrospective case reports of TC complicating end-stage renal disease (ESRD). RESULTS: We investigated STS treatment in four patients (two men; ages 46-70 years) with TC. ESRD was secondary to nephronophthisis (n = 1), membranoproliferative glomerulonephritis (n = 1), diabetic nephropathy (n = 1), and thrombotic microangiopathy (n = 1). TC developed 3-28 years after dialysis began and resulted in articular pain (n = 4) and stiffness (n = 1). It involved shoulders and hips and was diffuse in one patient. Several treatments were tried without success. STS 12.5-25 g was given intravenously after each dialysis session for 11-14 months. Pain and stiffness rapidly disappeared and TC showed partial or total regression. Side effects during infusion included increased blood pressure (n = 1), nausea (n = 1) and vomiting (n = 1). TC did not recur after treatment discontinuation with follow-up of 1.5-12 years. CONCLUSION: STS showed promising efficacy in this short series of TC. Further studies are warranted.
OBJECTIVE: The objective of this study was to describe the efficacy of sodium thiosulphate (STS) in tumoral calcinosis (TC). METHODS: The methodology involved the reporting of four retrospective case reports of TC complicating end-stage renal disease (ESRD). RESULTS: We investigated STS treatment in four patients (two men; ages 46-70 years) with TC. ESRD was secondary to nephronophthisis (n = 1), membranoproliferative glomerulonephritis (n = 1), diabetic nephropathy (n = 1), and thrombotic microangiopathy (n = 1). TC developed 3-28 years after dialysis began and resulted in articular pain (n = 4) and stiffness (n = 1). It involved shoulders and hips and was diffuse in one patient. Several treatments were tried without success. STS 12.5-25 g was given intravenously after each dialysis session for 11-14 months. Pain and stiffness rapidly disappeared and TC showed partial or total regression. Side effects during infusion included increased blood pressure (n = 1), nausea (n = 1) and vomiting (n = 1). TC did not recur after treatment discontinuation with follow-up of 1.5-12 years. CONCLUSION:STS showed promising efficacy in this short series of TC. Further studies are warranted.
Authors: Rakesh K Bijarnia; Matthias Bachtler; Prakash G Chandak; Harry van Goor; Andreas Pasch Journal: PLoS One Date: 2015-04-30 Impact factor: 3.240
Authors: Beatrice T Sponseller; David M Wong; Rebecca Ruby; Wendy A Ware; Scott Wilson; Joseph S Haynes Journal: J Vet Intern Med Date: 2022-07-08 Impact factor: 3.175